Lyell Immunopharma (LYEL) Other Non Operating Income (2020 - 2026)

Lyell Immunopharma has reported Other Non Operating Income for 7 years, with the latest figure at $17.9 million in Q1 2026.

• Quarterly Other Non Operating Income rose 1267.48% year-over-year to $17.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (down 130.93% YoY) and the FY2025 annual result came in at -$18.1 million, down 486.11% from the prior year.
• Other Non Operating Income climbed to $17.9 million in Q1 2026 per LYEL's latest filing, from -$15.8 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $17.9 million in Q1 2026 and troughed at -$15.8 million in Q4 2025.
• A 5-year average of $483352.9 and a median of $35000.0 in 2022 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2025: Other Non Operating Income jumped 6768.18% in 2022, then plunged 11200.0% in 2025.
• Over 5 years, Other Non Operating Income stood at $2.9 million in 2022, then sank by 117.25% to -$506000.0 in 2023, then surged by 948.22% to $4.3 million in 2024, then plunged by 467.08% to -$15.8 million in 2025, then soared by 213.7% to $17.9 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $17.9 million, -$15.8 million, and -$4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.